Fanning, IE
Neil O. Fanning, Cork IE
Patent application number | Description | Published |
---|---|---|
20100158028 | NETWORK SWITCH WITH MUTUALLY COUPLED LOOK-UP ENGINE AND NETWORK PROCESSOR - A network switch includes a look-up engine for obtaining associated data in response to a header portion of a packet and an interlinked network processor such as a RISC for performing a processing function on the header portion or the associated data. Both look-up engine and the network processor may modify a destination port bitmask. The network processor may implement additional packet header processing required for replication or server load balancing. | 06-24-2010 |
Neil O. Fanning, Kilworth IE
Patent application number | Description | Published |
---|---|---|
20120219000 | NETWORK SWITCH WITH MUTUALLY COUPLED LOOK-UP ENGINE AND NETWORK PROCESSOR - A network switch includes a look-up engine for obtaining associated data in response to a header portion of a packet and an interlinked network processor such as a RISC for performing a processing function on the header portion or the associated data. Both look-up engine and the network processor may modify a destination port bitmask. The network processor may implement additional packet header processing required for replication or server load balancing. | 08-30-2012 |
Niall Fanning, Coosan Athlone IE
Patent application number | Description | Published |
---|---|---|
20100136106 | Modified Release Famciclovir Compositions - The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers famciclovir in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment or suppression of viral infections. | 06-03-2010 |
Niall Fanning, Dublin IE
Patent application number | Description | Published |
---|---|---|
20090269400 | Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin - The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix. | 10-29-2009 |
20090297596 | Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor - The present invention provides a composition comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms. The invention provides a composition which comprises nanoparticulate particles comprising the platelet aggregation inhibitor and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a platelet aggregation inhibitor, or nanoparticles comprising the same, in a pulsatile or continuous manner. | 12-03-2009 |
Niall M.m. Fanning, Westmeath IE
Patent application number | Description | Published |
---|---|---|
20110008435 | Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds - The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders. | 01-13-2011 |
Niall M.m. Fanning, Swords IE
Patent application number | Description | Published |
---|---|---|
20100247636 | Nanoparticulate and controlled release compositions comprising nilvadipine - The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders. | 09-30-2010 |
Niall M.n. Fanning, Coosan Athlone IE
Patent application number | Description | Published |
---|---|---|
20110064803 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2 - The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis. | 03-17-2011 |
Niall M.n. Fanning, County Westmeath IE
Patent application number | Description | Published |
---|---|---|
20090297597 | Modified Release Ticlopidine Compositions - The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient. | 12-03-2009 |
20090297602 | Modified Release Loxoprofen Compositions - The invention relates to a modified release composition comprising loxoprofen or a salt or derivative thereof that in operation delivers the drug in a pulsatile or continuous manner for the treatment of pain and/or inflammation. The composition may comprise a first loxoprofen component and one subsequent loxoprofen component, wherein the first loxoprofen component comprises an immediate release component and the subsequent loxoprofen component comprises a modified release component. | 12-03-2009 |
Nial M. N. Fanning, Raheny IE
Patent application number | Description | Published |
---|---|---|
20080279929 | Nanoparticulate and Controlled Release Compositions Comprising Cefditoren - The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner. | 11-13-2008 |